BCG vaccine

DB12768ApprovedInvestigationalWithdrawnVaccines

BCG vaccine is a vaccine indicated in the prevention of tuberculosis and the treatment of non-invasive urothelial bladder cancer. BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.

First approval: Canada, 2004
Also known as: Bacillus Calmette Guerin · Bacillus Calmette-Guérin · Bacillus calmette-guerin live antigen, unspecified substrain · Bacillus Calmette–Guérin (BCG) vaccine · BCG

Resolves to

Compound

UNII8VJE55B0VG

Clinical / RWD

RxNorm1344ATCL03AX03

What you can answer from here — as of October 09, 2025

745Drug interactionsStructured to mechanism, not free text

196Clinical trialsPhase, status and sponsor resolved per trial

5Structured indicationsCondition, population, route and combination as fields, not prose

10ContraindicationsEach with its own population and attribute set

28Marketed productsAcross 7 countries and 14 labellers

1ATC codeIncluding every combination product, plus 12 drug categories

2+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as BCG vaccine, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account